472 related articles for article (PubMed ID: 17128427)
1. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
Carroll KJ
Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
[TBL] [Abstract][Full Text] [Related]
2. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
D'Agostino RB; Massaro JM; Sullivan LM
Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
[TBL] [Abstract][Full Text] [Related]
3. TACT method for non-inferiority testing in active controlled trials.
Wang SJ; Hung HM
Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
[TBL] [Abstract][Full Text] [Related]
4. A ratio test in active control non-inferiority trials with a time-to-event endpoint.
Wang YC; Chen G; Chi GY
J Biopharm Stat; 2006; 16(2):151-64. PubMed ID: 16584064
[TBL] [Abstract][Full Text] [Related]
5. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
Sankoh AJ
Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
[TBL] [Abstract][Full Text] [Related]
6. Assessing non-inferiority: a combination approach.
Gao P; Ware JH
Stat Med; 2008 Feb; 27(3):392-406. PubMed ID: 17575568
[TBL] [Abstract][Full Text] [Related]
7. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.
Pigeot I; Schäfer J; Röhmel J; Hauschke D
Stat Med; 2003 Mar; 22(6):883-99. PubMed ID: 12627407
[TBL] [Abstract][Full Text] [Related]
8. On non-inferiority margin and statistical tests in active control trials.
Chow SC; Shao J
Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
[TBL] [Abstract][Full Text] [Related]
9. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
Hirotsu C
Pharm Stat; 2007; 6(3):193-203. PubMed ID: 17879327
[TBL] [Abstract][Full Text] [Related]
10. A mixed approach for proving non-inferiority in clinical trials with binary endpoints.
Rousson V; Seifert B
Biom J; 2008 Apr; 50(2):190-204. PubMed ID: 18311852
[TBL] [Abstract][Full Text] [Related]
11. [Methodological and statistical aspects of equivalence and non inferiority trials].
Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
[TBL] [Abstract][Full Text] [Related]
12. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
Dilba G; Bretz F; Hothorn LA; Guiard V
Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
[TBL] [Abstract][Full Text] [Related]
13. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
Schwartz TA; Denne JS
Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
[TBL] [Abstract][Full Text] [Related]
14. Design and analysis of non-inferiority mortality trials in oncology.
Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
[TBL] [Abstract][Full Text] [Related]
15. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
Lai TL; Shih MC; Zhu G
Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
[TBL] [Abstract][Full Text] [Related]
16. Non-inferiority trials: the 'at least as good as' criterion with dichotomous data.
Laster LL; Johnson MF; Kotler ML
Stat Med; 2006 Apr; 25(7):1115-30. PubMed ID: 16381070
[TBL] [Abstract][Full Text] [Related]
17. Current issues in non-inferiority trials.
Fleming TR
Stat Med; 2008 Feb; 27(3):317-32. PubMed ID: 17340597
[TBL] [Abstract][Full Text] [Related]
18. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
Durkalski VL; Berger VW
Biom J; 2009 Feb; 51(1):185-92. PubMed ID: 19197960
[TBL] [Abstract][Full Text] [Related]
19. Methodology of superiority vs. equivalence trials and non-inferiority trials.
Christensen E
J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
[TBL] [Abstract][Full Text] [Related]
20. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
